Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 28 min 37 sec ago

Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting

Fri, 05/29/2015 - 15:22
Myriad myRisk Finds >60 Percent More Mutations Than BRCA1/2 Testing in Multiple Studies SALT LAKE CITY, May 29, 2015 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today announced it will highlight several new clinical stud...
Diagnostics, Oncology
Myriad Genetics, myRisk Hereditary Cancer, hereditary cancer

Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease

Fri, 05/29/2015 - 15:12
Pivotal Phase 3 Data Highlight Safety, Efficacy of AMG 416 Significant Reductions in Parathyroid Hormone Concentrations Observed in Hemodialysis Patients Global Regulatory Filings Planned for 2015 THOUSAND OAKS, Calif., May 29, 2015 -- (Healthcare...
Amgen, AMG 416, calcimimetic, hyperparathyroidism, chronic kidney disease

Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer

Thu, 05/28/2015 - 14:12
Company to expand the commercialization of ClearPath DS-120® under new leadership SAN DIEGO, May 28, 2015 -- (Healthcare Sales & Marketing Network) -- Freedom Meditech, Inc., a medical device company transforming the diagnosis and monitoring of chr...
Devices, Venture Capital, Personnel
Freedom Meditech, ClearPath DS-120 Lens, Biomicroscope

Pronutria Biosciences Raises $39 Million in Series C Financing

Thu, 05/28/2015 - 14:00
Proceeds will Advance Clinical Development Programs for Multiple Therapeutic Areas CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Pronutria Biosciences, a clinical stage biotechnology company pioneering a new class of therapeutics to mediate ...
Biopharmaceuticals, Venture Capital
Pronutria Biosciences

NeuWave Medical Inc. Closes $25 Million in New Financing

Thu, 05/28/2015 - 13:51
Series C Round to Accelerate Commercial and R&D Expansion Plans MADISON, Wis. & MINNEAPOLIS--(Healthcare Sales & Marketing Network)--NeuWave Medical® Inc., a privately held medical device company focused on developing disruptive technology for use i...
Devices, Venture Capital
NeuWave Medical, Intelligent Ablation System, microwave ablation

Mazor Robotics’ Renaissance System Highlighted in Special Session at the Joint Congress of the Chinese Association of Orthopaedic Surgeons and North American Spine Society

Thu, 05/28/2015 - 13:41
Leading American Surgeon Demonstrated Robotic-guided Spine Surgery to 1,000 Surgeons CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics (TASE:MZOR; NASDAQ GM:MZOR), a developer of innovative guidance systems and complementary produ...
Devicecs, Neurosurgery, Orthopaedic
Mazor Robotics, Renaissance system, spine surgery, robotic surgery

Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory

Wed, 05/27/2015 - 14:25
BOSTON, May 27, 2015 -- (Healthcare Sales & Marketing Network) -- Zafgen, Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced the ...
Biopharmaceuticals, Personnel
Zafgen, Beloranib, Prader-Willi syndrome, obesity

Boston Scientific Names Prof. John Mark Morgan as Senior Medical Director, Rhythm Management

Wed, 05/27/2015 - 14:20
PARIS, May 27, 2015 -- (Healthcare Sales & Marketing Network) --Boston Scientific Corporation (BSX) announces the appointment of Professor John Mark Morgan as senior medical director, Rhythm Management, effective from September 1st, 2015. Prof. Morgan,...
Devices, Cardiology, Personnel
Boston Scientific, cardiac rhythm management, pacemaker, ICD

The European Commission Approves ALOXI(R) (palonosetron HCl) Injection to Prevent Nausea and Vomiting Due to Chemotherapy in Children as Young as One Month

Wed, 05/27/2015 - 14:12
The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of ALOXI® for paediatric use in the US LUGANO, Switzerland, May 27, 2015 -- (Healthcare Sales & Marketing Network) -- Helsinn Group, the Swiss Group focus...
Biopharmaceuticals, Oncology, Regulatory
Helsinn Group, ALOXI, palonosetron, CINV

Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF(TM) US Pivotal Study for C-Pulse(R) Heart Assist System

Tue, 05/26/2015 - 13:52
EDEN PRAIRIE, Minn., May 26, 2015 -- (Healthcare Sales & Marketing Network) -- Sunshine Heart, Inc. (SSH) is pleased to announce that the US Food and Drug Administration (FDA) has approved the resumption of patient enrollment in its COUNTER HF US pivotal s...
Devices, Cardiology, FDA
Sunshine Heart, COUNTER HF, C-Pulse, balloon counterpulsation

CVRx(R) Barostim Therapy(R) for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference

Tue, 05/26/2015 - 13:44
INNEAPOLIS, May 26, 2015 -- (Healthcare Sales & Marketing Network) -- CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the 2...
Devices, Cardiology
CVRx, Barostim Therapy, Barostim neo, heart failure, resistant hypertension

Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile

Tue, 05/26/2015 - 13:31
New test expands menu for healthcare associated infections testing on the widely adopted cobas® 4800 System PLEASANTON, Calif., May 26, 2015 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US...
Diagnostics, FDA
Roche Group, Clostridium difficile, cobas , Cdiff Test

Omidria(R) Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

Fri, 05/22/2015 - 14:49
Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile SEATTLE, May 22, 2015 -- (Healthcare Sales & Marketing Network) -- Omeros Corporation (OMER), a biopharmaceutical company committed to discover...
Biopharmaceuticals, Ophthalmology, Regulatory
Omeros Corp, Omidria, mydriasis, PharmacoSurgery

Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer

Thu, 05/21/2015 - 13:27
Accomplished drug hunter takes helm of synthetic biology leader as company advances lead therapeutic microbe programs toward clinical testing and executes path to drug discovery platform expansion Company debuts rare disease focused pipeline with two pr...
Biopharmaceuticals, Personnel
Synlogic, therapeutic synthetic life

Mitralign Shows Positive Mitral Data at PCR

Thu, 05/21/2015 - 13:17
Mitralign Percutaneous Annuloplasty System shows improved valve function at six month; company anticipates CE marking in mid-2015 PARIS & TEWKSBURY, Mass.--(Healthcare Sales & Marketing Network)--Mitralign shared six month data on its Mitralign Percutan...
Devices, Interventional Cardiology
Mitralign, Percutaneous Annuloplasty, transcatheter annuloplasty

Ampio Pharmaceuticals Announces Positive Study Results on Optina(TM) for the Treatment of Diabetic Macular Edema

Thu, 05/21/2015 - 13:08
ENGLEWOOD, Colo., May 21, 2015 -- (Healthcare Sales & Marketing Network) -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controll...
Biopharmaceuticals, Ophthalmology
Ampio Pharmaceuticals, OptimEyes, Optina, Diabetic Macular Edema

Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel(TM) XR

Thu, 05/21/2015 - 11:46
The First, Once-Daily, Extended-Release Amphetamine-based Oral Liquid for the Treatment of ADHD MONMOUTH JUNCTION, N.J., May 21, 2015 -- (Healthcare Sales & Marketing Network) -- Tris Pharma, Inc. ("Tris") announced that U.S. Food and Drug Ad...
Biopharmaceuticals, Drug Delivery
Tris Pharma, Dyanavel XR, LiquiXR, ADHD

Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

Thu, 05/21/2015 - 11:36
Includes study in patients who were inadequate responders to or intolerant of TNF-alpha inhibitors U.S. regulatory submission planned for Q4 2015 TARRYTOWN, N.Y. and PARIS, May 21, 2015 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmace...
Regeneron Pharmaceuticals, Sanofi, sarilumab, rheumatoid arthritis

EnteroMedics Announces First US Commercial Implant of vBloc(R) Neurometabolic Therapy System at Tufts Medical Center in Boston, Massachusetts

Wed, 05/20/2015 - 19:37
. PAUL, Minn., May 20, 2015 -- (Healthcare Sales & Marketing Network) -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced t...
EnteroMedics, neuroblocking, Maestro, vBloc , Neurometabolic Therapy

Dassault Systèmes Announces Commercial Availability of Its First Simulated Human Heart

Wed, 05/20/2015 - 13:48
Scientifically Accurate 3D Model Accelerates Device Testing and Research for Treatment of Heart Disease ÉLIZY-VILLACOUBLAY, France & BERLIN--(Healthcare Sales & Marketing Network)--Dassault Systèmes (Paris:DSY) (Euronext Paris: #13065, DSY...
Devices, Cardiology, Product Launch
Dassault Systèmes, Living Heart Project

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong